Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

EPIGENETICS

SETDB1, a new target for immunotherapy

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ulrike Harjes.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harjes, U. SETDB1, a new target for immunotherapy. Nat Rev Cancer 21, 412 (2021). https://doi.org/10.1038/s41568-021-00373-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41568-021-00373-x

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer